However, in advanced CML, neoplastic cells may even be resistant against ponatinib or asciminib, especially when these cells exhibit complex molecular aberration‐patterns or BCR::ABL1 compound mutations.23, 24, 25. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.